Adrian P Gee
Overview
Explore the profile of Adrian P Gee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
8770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
da Graca Cabreira M, Wang X, Critsinelis A, Setegne M, Lotfi P, Wan Y, et al.
Cytotherapy
. 2022 Sep;
24(12):1201-1210.
PMID: 36109320
Background Aims: Stem and progenitor cells of hematopoietic and mesenchymal lineages reside in the bone marrow under low oxygen (O) saturation. O levels used in ex vivo expansion of multipotent...
2.
Steffin D, Muhsen I, Hill L, Ramos C, Ahmed N, Hegde M, et al.
Blood
. 2022 Mar;
140(1):16-24.
PMID: 35325065
Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells have shown benefit in hematologic malignancies and are being evaluated in clinical...
3.
El Fiky A, Ibenana L, Anderson R, Hare J, Khan A, Gee A, et al.
Clin Transl Sci
. 2021 Jul;
14(6):2099-2110.
PMID: 34286927
The Production Assistance for Cellular Therapies (PACT) Program, is funded and supported by the US Department of Health and Human Services' National Institutes of Health (NIH) National Heart Lung and...
4.
Bolli R, Mitrani R, Hare J, Pepine C, Perin E, Willerson J, et al.
Eur J Heart Fail
. 2021 Apr;
23(4):661-674.
PMID: 33811444
Aims: CONCERT-HF is an NHLBI-sponsored, double-blind, placebo-controlled, Phase II trial designed to determine whether treatment with autologous bone marrow-derived mesenchymal stromal cells (MSCs) and c-kit positive cardiac cells (CPCs), given...
5.
Vasileiou S, Lulla P, Tzannou I, Watanabe A, Kuvalekar M, Callejas W, et al.
J Clin Oncol
. 2021 Jan;
39(13):1415-1425.
PMID: 33507803
Purpose: Patients with relapsed lymphomas often fail salvage therapies including high-dose chemotherapy and mono-antigen-specific T-cell therapies, highlighting the need for nontoxic, novel treatments. To that end, we clinically tested an...
6.
Bolli R, Perin E, Willerson J, Yang P, Traverse J, Henry T, et al.
JACC CardioOncol
. 2021 Jan;
2(4):581-595.
PMID: 33403362
Background: Anthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) is a promising approach...
7.
Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani S, et al.
Front Cell Dev Biol
. 2021 Jan;
8:547653.
PMID: 33392179
The introduction of advanced therapy medicinal products (ATMPs) to the global pharma market has been revolutionizing the pharmaceutical industry and has opened new routes for treating various types of cancers...
8.
Lulla P, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, et al.
Blood
. 2020 Dec;
137(19):2585-2597.
PMID: 33270816
Relapse after allogeneic hematopoietic stem cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Infusion of unselected donor lymphocytes...
9.
Lulla P, Tzannou I, Vasileiou S, Carrum G, Ramos C, Kamble R, et al.
Sci Transl Med
. 2020 Jul;
12(554).
PMID: 32727914
Multiple myeloma (MM) is an almost always incurable malignancy of plasma cells. Despite the advent of new therapies, most patients eventually relapse or become treatment-refractory. Consequently, therapies with nonoverlapping mechanisms...
10.
Ramos C, Grover N, Beaven A, Lulla P, Wu M, Ivanova A, et al.
J Clin Oncol
. 2020 Jul;
38(32):3794-3804.
PMID: 32701411
Purpose: Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can...